Business

Investor based on Moderna raises $ 3.4 billion biotechnology fund


Flagship Pioneering, Moderna’s venture capital company, has raised its largest fund as it aims to build the next generation of biotech companies.

The $ 3.4 billion fund is one of the largest fundraisers in the pharmaceutical industry – it comes at a time of investment is flooding the field, powered by many early stage companies race prepare treatments և vaccines to treat Covid-19.

Flagship founder Nubar Afeyan said. “The expanded capital base will allow us. “, to pioneer science, create companies և growth – all under one roof.”

Flagship Fund VII consists of $ 2.2 billion invested this year and 1.2 $ 1.2 billion in 2020. The company plans to invest cash over the next three years.

Instead of funding early-stage biotechnology for hunting, the Massachusetts-based group is investing in technology development and building companies within its own four walls. Teams are built around specific areas of interest, with the goal of developing separate companies to develop research.

Coronavirus business update

How does the coronavirus cause harm from markets, businesses, our daily lives, and our workplaces? Stay tuned for more information on our coronavirus newsletter.

Register here:

“It’s not an investment fund in the traditional sense of the word. “None of what we do comes from abroad,” Afeyan, who founded Flagship in 2000, told the Financial Times. “It is dedicated to advancing each of our biological platforms that we invent in our homes.”

Flagship’s most popular company is Moderna, which was founded in 2010 to develop mRNA therapy and is chaired by Afeyan. The vaccine manufacturer has been sold Covidian clasps worth $ 1.7 billion In the first three months of the year, և its share price has exceeded more than 1000% since 2020.

Afeyan described Flagship’s strategy as “research” և “an unlimited attempt to make scientific advances as product progress”. He said that he started developing vaccines at Moderna by asking: “Can we use a code molecule or a molecule that can instruct the body to make any drug we want?”

Flagship has $ 14.1 billion in assets under management and has spent $ 4.8 billion on its companies in the last four quarters. Last week, Valo Health, its drug discovery company, announced that it would be released to the public by joining a special purpose acquisition company.

Afeyan noted that the Life Sciences Society does not focus on creating biotechnologies that will eliminate specific diseases, but instead seeks to build platforms where the technologies can be used in a number of diseases. Moderna is currently testing the first phase of its mRNA technology for HIV:.

Leading scientists have been particularly interested in advancing machine learning tools that can provide a more sophisticated, more detailed understanding of the human body than humans, as well as the field of preventive medicine.

“Underlying health conditions made this epidemic a disaster because there were all these underlying health conditions that were making it worse,” he said. “We believe that in the future we will see a world where we can intervene before diseases appear.”

Flagship has recently expanded, opening an office in London and hiring Lord Ara Darcy, a former UK health minister, to lead its precautionary medicine work.



Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button